Department of Urology, The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510230, China
NCT Number: NCT05952635
Nephrolithiasis is the most common chronic kidney condition and affecting approximately one in every 10-17 people in the world[1,2]. Flexible ureteroscopy (f-URS) has become one of the most common treatments for ureteral and renal stones with minimal complications. The development of ureteral access sheath (UAS) is a significant advance in flexible ureteroscopic management of urinary stones. The UAS has two major advantages: 1) facilitating multiple entries into the renal collecting system without causing recurrent trauma to the ureter and permit expeditious basketing of multiple stone fragments, 2) improving the irrigation with better fluid outflow, thereby reducing the renal pelvic pressure (RPP) and risk of infectious complications.
The tip bendable suction ureteral access sheath (S-UAS) is a novel UAS that has good flexibility and deformability at the tip, which can passively bend (bend >90°) with the bending of f-URS and can connect to a vacuum suction device. Preliminary study showed that S-UAS can follow f-URS to cross the UPJ and into the renal pelvis and calices. S-UAS close to the stone can achieve complete stone-free status in RIRS. However, further clinical studies and comparisons with available techniques are required. This prospective, single-blinded, single-center, randomized control trial will evaluate the stone free rates, operative time, postoperative complications following RIRS with S-UAS. To the best of our knowledge, this is the first study to compare the clinical benefits of RIRS with S-UAS and traditional UAS.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Guangzhou, Guangdong, 510230, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patient use tip bendable suction ureteral access sheath during flexible ureteroscopy to see if flexible ureteroscopy with S-UAS offers the better treatment outcomes in terms of clinical effectiveness and post-operative complications.
Time frame: Postoperative day 1
No residual stone, or no stone fragments larger than 2 mm on KUB and ultrasound at postoperative day 1 are defined as stone free.
Time frame: Postoperative 3 month
No residual stone, or no stone fragments larger than 2 mm on CT scan at postoperative 3 month are defined as stone free.
Time frame: From date of operation until the date of discharge, assessed up to 2 weeks.
Time frame: Postoperative 3 month
Time frame: Postoperative 3 month
Time frame: Postoperative 3 month
Time frame: From start of operation until the end of operation, assessed up to 2 weeks.
The duration from the insertion of the endoscope into the urethra to the completion of stent placement.
The First Affiliated Hospital of Guangzhou Medical University
Other
Tip Bendable Suction Ureteral Access Sheath vs. Traditional Ureteral Access Sheath in Retrograde Intrarenal Stone Surgery (RIRS): Study Protocol of a Multicentre, Prospective, Single-blinded, Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04051346
Calculi, Female Urogenital Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06269783
Calculi, Female Urogenital Diseases
University Park, Pennsylvania, United States
View Trial DetailsNCT07566416
Calculi, Female Urogenital Diseases
Ankara, Altındağ, Turkey (Türkiye)
View Trial DetailsNCT04997668
Calculi, Female Urogenital Diseases
Kansas City, Kansas, United States
View Trial Details